Bálint Szokol

407 total citations
20 papers, 308 citations indexed

About

Bálint Szokol is a scholar working on Molecular Biology, Oncology and Organic Chemistry. According to data from OpenAlex, Bálint Szokol has authored 20 papers receiving a total of 308 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 6 papers in Oncology and 4 papers in Organic Chemistry. Recurrent topics in Bálint Szokol's work include Lung Cancer Treatments and Mutations (3 papers), Tuberculosis Research and Epidemiology (2 papers) and Fibroblast Growth Factor Research (2 papers). Bálint Szokol is often cited by papers focused on Lung Cancer Treatments and Mutations (3 papers), Tuberculosis Research and Epidemiology (2 papers) and Fibroblast Growth Factor Research (2 papers). Bálint Szokol collaborates with scholars based in Hungary, Netherlands and Germany. Bálint Szokol's co-authors include László Őrfi, Gÿorgý Kéri, János Pató, Robbert J. Kok, Csaba Szántai-Kis, István Szabadkai, Gábor Németh, Armin Hoell, Bert Klebl and Eszter Illyés and has published in prestigious journals such as The Journal of Physical Chemistry B, European Journal of Medicinal Chemistry and Current Medicinal Chemistry.

In The Last Decade

Bálint Szokol

20 papers receiving 298 citations

Peers

Countries citing papers authored by Bálint Szokol

Since Specialization

Citations

This map shows the geographic impact of Bálint Szokol's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bálint Szokol with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bálint Szokol more than expected).

Fields of papers citing papers by Bálint Szokol

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bálint Szokol. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bálint Szokol. The network helps show where Bálint Szokol may publish in the future.

Co-authorship network of co-authors of Bálint Szokol

This figure shows the co-authorship network connecting the top 25 collaborators of Bálint Szokol. A scholar is included among the top collaborators of Bálint Szokol based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bálint Szokol. Bálint Szokol is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The role of PI3K-Akt-mTOR axis in Warburg effect and its modification by specific protein kinase inhibitors in human and rat inflammatory macrophages 2024 ·International Immunopharmacology ·(unknown), (unknown), (unknown), Bálint Szokol, Zoltán Kukor, Tamás Kardon, László Őrfi, László Tretter, András Hrabák	6
2	Decreasing effects of protein kinase inhibitors on the expression of NOS2 and inflammatory cytokines and on phagocytosis in rat peritoneal macrophages is partly related to repolarization 2022 ·Molecular Immunology ·András Hrabák, (unknown), (unknown), Viola Tamási, Krisztína Németh, Bálint Szokol, Zoltán Kukor, Tamás Kardon, László Őrfi	4
3	EGFR Alterations Influence the Cetuximab Treatment Response and c-MET Tyrosine-Kinase Inhibitor Sensitivity in Experimental Head and Neck Squamous Cell Carcinomas 2021 ·Pathology & Oncology Research ·(unknown), Mihály Cserepes, Balázs Szabó, Dóra Türk, (unknown), István Kenessey, Erzsébet Rásó, Tamás Barbai, (unknown), Viktória László, Bálint Szokol, Judit Dobos, László Őrfi, József Tóvári	3
4	Production of NOS2 and inflammatory cytokines is reduced by selected protein kinase inhibitors with partial repolarization of HL-60 derived and human blood macrophages 2021 ·Heliyon ·(unknown), (unknown), Bálint Szokol, Zoltán Kukor, (unknown), Tamás Kardon, László Őrfi, András Hrabák	8
5	Synthesis and Structure–Activity relationship of 1-(5-isoquinolinesulfonyl)piperazine analogues as inhibitors of Mycobacterium tuberculosis IMPDH 2019 ·European Journal of Medicinal Chemistry ·Vinayak Singh, A. Pacitto, Stefano Donini, Davide M. Ferraris, (unknown), Eszter Illyés, Bálint Szokol, Menico Rizzi, Tom L. Blundell, David B. Ascher, János Pató, Valerie Mizrahi	19
6	Novel compounds with potent CDK9 inhibitory activity for the treatment of myeloma 2018 ·Bioorganic & Medicinal Chemistry Letters ·(unknown), M. BALOGH, (unknown), (unknown), (unknown), Judit Dobos, (unknown), Zoltán Horváth, Eszter Illyés, (unknown), (unknown), Csaba Szántai-Kis, Bálint Szokol, László Őrfi	19
7	Synthesis and characterization of amino acid substituted sunitinib analogues for the treatment of AML 2018 ·Bioorganic & Medicinal Chemistry Letters ·Zoltán Nemes, Krisztina Takács‐Novák, Gergely Völgyi, Klára Valkó, Szabolcs Béni, Zoltán Horváth, Bálint Szokol, (unknown), Judit Dobos, Csaba Szántai-Kis, Eszter Illyés, (unknown), Robbert J. Kok, László Őrfi	8
8	Discovery and optimization of novel benzothiophene-3-carboxamides as highly potent inhibitors of Aurora kinases A and B 2018 ·Bioorganic & Medicinal Chemistry Letters ·(unknown), Bálint Szokol, István Szabadkai, (unknown), (unknown), (unknown), (unknown), (unknown), Eszter Illyés, Csaba Szántai-Kis, (unknown), (unknown), László Őrfi	4
9	Development of a 3D Tissue Culture–Based High-Content Screening Platform That Uses Phenotypic Profiling to Discriminate Selective Inhibitors of Receptor Tyrosine Kinases 2016 ·SLAS DISCOVERY ·Tijmen H. Booij, (unknown), Kuan Yan, Csaba Szántai-Kis, Bálint Szokol, László Őrfi, Bob van de Water, Gÿorgý Kéri, Leo Price	18
10	Discovery and Biological Evaluation of Novel Dual EGFR/c-Met Inhibitors 2014 ·ACS Medicinal Chemistry Letters ·Bálint Szokol, (unknown), (unknown), Ferenc Baska, Csaba Szántai-Kis, Zoltán Greff, (unknown), (unknown), (unknown), Robert Torka, Axel Ullrich, László Őrfi, Tibor Vántus, Gÿorgý Kéri	12
11	Developing FGFR4 Inhibitors As Potential Anti-Cancer Agents Via In Silico Design, Supported by In Vitro and Cell-Based Testing 2013 ·Current Medicinal Chemistry ·Han Kiat Ho, (unknown), (unknown), Emily M. Pang, Csaba Szántai-Kis, (unknown), (unknown), Zoltán Greff, (unknown), (unknown), István Szabadkai, Bálint Szokol, Ferenc Baska, László Őrfi, A. Ullrich, Gÿorgý Kéri, Boon Tin Chua	12
12	[Development and biochemical characterization of EGFR/c-Met dual inhibitors]. 2013 ·PubMed ·Bálint Szokol, (unknown), Ferenc Baska, (unknown), Zoltán Greff, Csaba Szántai-Kis, (unknown), István Peták, Axel Ullrich, Tibor Vántus, Gÿorgý Kéri, László Őrfi	1
13	Targeting of a platinum-bound sunitinib analog to renal proximal tubular cells 2012 ·International Journal of Nanomedicine ·Robbert J. Kok, (unknown), (unknown), (unknown), (unknown), (unknown), Bálint Szokol, László Őrfi, (unknown), (unknown), (unknown)	35
14	Dendrimer‐Based Macromolecular Conjugate for the Kidney‐Directed Delivery of a Multitargeted Sunitinib Analogue 2011 ·Macromolecular Bioscience ·M. Emmy M. Dolman, (unknown), Ebel H. E. Pieters, Rolf W. Sparidans, M. Lacombe, Bálint Szokol, László Őrfi, Gÿorgý Kéri, Niels Bovenschen, Gert Storm, Wim E. Hennink, Robbert J. Kok	18
15	Development of a Cell-Selective and Intrinsically Active Multikinase Inhibitor Bioconjugate 2011 ·Bioconjugate Chemistry ·Stefan Harmsen, M. Emmy M. Dolman, Zoltán Nemes, M. Lacombe, Bálint Szokol, János Pató, Gÿorgý Kéri, László Őrfi, Gert Storm, Wim E. Hennink, Robbert J. Kok	18
16	Inhibition of c-Met with the Specific Small Molecule Tyrosine Kinase Inhibitor SU11274 Decreases Growth and Metastasis Formation of Experimental Human Melanoma 2010 ·Current Cancer Drug Targets ·István Kenessey, (unknown), Zachary Kramer, Judit Berta, Ammar Adam, Judit Dobos, Michael Mildner, Beáta Flachner, Sándor Cseh, Gábor Barna, Bálint Szokol, László Őrfi, (unknown), Balázs Döme, Walter Klepetko, József Tı́már, József Tóvári	26
17	A Closer Look at the Structure of Sterically Stabilized Liposomes: A Small-Angle X-ray Scattering Study 2010 ·The Journal of Physical Chemistry B ·Zoltán Varga, (unknown), Bálint Szokol, László Őrfi, Gÿorgý Kéri, István Peták, Armin Hoell, Attila Bóta	31
18	A novel drug discovery concept for tuberculosis: Inhibition of bacterial and host cell signalling 2008 ·Immunology Letters ·Rita Székely, (unknown), István Szabadkai, Gábor Németh, (unknown), Dániel Erös, Bálint Szokol, János Pató, Doris Hafenbradl, (unknown), Brigitte Saint‐Joanis, Stewart T. Cole, László Őrfi, Bert Klebl, Gÿorgý Kéri	62
19	A facile synthesis of 5(6)‐(chloromethyl)benzimidazoles: Replacement of a sulfonic acid functionality by chlorine 2008 ·Journal of Heterocyclic Chemistry ·(unknown), Bálint Szokol, (unknown)	3
20	A facile synthesis of 4-, 6- and 7-formyl-1H-indole-2-carboxylates: The CH₂SO₃H functionality as a masked formyl group 2006 ·Journal of Heterocyclic Chemistry ·(unknown), Bálint Szokol, (unknown)	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact